News Author: Erilyn Riley Publish date: January 2, 2015
Credit: NIAID
SAN FRANCISCO—CTL019, a chimeric antigen receptor (CAR) T cell targeting CD19, is not the only CAR in the production line.
Investi...
News Author: Erilyn Riley Publish date: January 2, 2015
Credit: Bill Branson
SAN FRANCISCO—A chimeric antigen receptor (CAR) T-cell therapy is feasible in 90% of heavily pretreated or transplanted patien...
News Author: Erilyn Riley Publish date: January 2, 2015
Credit: Charles Haymond
SAN FRANCISCO—JCAR015, a chimeric antigen receptor (CAR) T-cell therapy, can produce durable responses in patients with B-c...
News Author: Erilyn Riley Publish date: December 24, 2014
SAN FRANCISCO—Two monoclonal antibodies that block the programmed death-1 (PD-1) pathway are showing promise in early phase trials in relapsed/refract...
News Author: Erilyn Riley Publish date: December 19, 2014
Photo courtesy of ASH
SAN FRANCISCO—Two recent studies have shown combination therapy with brentuximab vedotin to be highly active in newly diagnos...
News Author: Erilyn Riley Publish date: December 18, 2014
in the Moscone Center
SAN FRANCISCO—The first-in-human study of AG-221 has confirmed IDH2 as a therapeutic target in acute myeloid leukemia (AML) a...
News Author: Erilyn Riley Publish date: December 17, 2014
SAN FRANCISCO—The first international, multicenter trial in acute lymphoblastic leukemia (ALL) using minimal residual disease (MRD) as a criterion for...
News Author: Erilyn Riley Publish date: December 16, 2014
Researchers at the University of Pennsylvania, working with CTL019 cells, are beginning to see both of these phenomena in children with relapsed, refr...
News Author: Erilyn Riley Publish date: December 12, 2014
site of the ASH Annual Meeting
Photo courtesy of ASH
SAN FRANCISCO—Two activin receptor fusion proteins, luspatercept and sotatercept, increased h...
News Author: Erilyn Riley Publish date: December 11, 2014
Photo courtesy of ASH
SAN FRANCISCO—Researchers have presented the first randomized evidence that kinase inhibitors are effective in the treatment ...
News Author: Erilyn Riley Publish date: December 10, 2014
Photo courtesy of ASH
SAN FRANCISCO—Results regarding daunorubicin escalation in induction for patients with acute myeloid leukemia (AML) have vari...
News Author: Erilyn Riley Publish date: November 3, 2014
NEW YORK—The role of allogeneic hematopoietic stem cell transplant (HSCT) for patients with high-risk chronic lymphocytic leukemia (CLL) is chan...
News Author: Erilyn Riley Publish date: October 31, 2014
NEW YORK—Calling the synergy with the proteasome inhibitor “profound,” Paul G.
News Author: Erilyn Riley Publish date: October 30, 2014
NEW YORK—With both the pro and con positions drawing on data from the phase 3 CLL11 trial, two speakers at the Lymphoma & Myeloma2014 congress fac...
News Author: Erilyn Riley Publish date: October 28, 2014
NEW YORK—Chimeric antigen receptor (CAR) T cells have “remarkable” activity, according to a speaker at the NCCN 9th Annual Congress: Hematologic Malig...
